From Wikipedia, the free encyclopedia
The combination preparation ipratropium/salbutamol is a formulation containing ipratropium bromide and salbutamol sulfate (albuterol sulfate) used in the management of chronic obstructive pulmonary disease (COPD) and asthma. It is marketed by Boehringer Ingelheim as metered dose inhaler (MDI) and nebuliser preparations under the trade name Combivent.
|
Medications commonly used in asthma and COPD (primarily R03) |
| Anticholinergics |
Ipratropium, Tiotropium |
| Short acting β2-agonists |
Salbutamol, Terbutaline |
| Long acting β2-agonists (LABA) |
Bambuterol, Clenbuterol, Fenoterol, Formoterol, Salmeterol |
| Corticosteroids |
Beclometasone, Budesonide, Ciclesonide, Fluticasone |
| Leukotriene antagonists |
Montelukast, Pranlukast, Zafirlukast |
| Xanthines |
Aminophylline, Theobromine, Theophylline |
| Mast cell stabilizers |
Cromoglicate, Nedocromil |
| Combination products |
Budesonide/formoterol, Fluticasone/salmeterol, Ipratropium/salbutamol |
